Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawal of Tiratricol in Males with MCT8 Deficiency (ReTRIACt)
2024-516124-34-00Phase 3Completed
- Sponsor
- Egetis Therapeutics
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Allan-Herndon-Dudley syndrome (AHDS) comparing Tiratricol arm with Matching placebo arm (2 arms). Primary endpoints: Rate of change in serum total T3 during randomized treatment and Rescue criterion based on serum total T3. Started Sep 2024; status: completed.
02
Drugs
tiratricol
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on 2024-516124-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516124-34-00.